| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/13/2009 | CN101432023A Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies |
| 05/13/2009 | CN101432022A Methods for damaging cells using effector functions of anti-epha4 antibodies |
| 05/13/2009 | CN101432021A Composition comprising an antigen-recognizing molecule and a lipid-based carrier |
| 05/13/2009 | CN101432020A Methods and materials for the inhibition of transplant rejection |
| 05/13/2009 | CN101432019A Treatment and prevention of hypersensitivity and/or anaphylaxis with anti-IgE antibodies in patients receiving replacement therapy |
| 05/13/2009 | CN101432018A IL-13 binding agents |
| 05/13/2009 | CN101432017A Polypeptides for inducing a protective immune response against staphylococcus aureus |
| 05/13/2009 | CN101432016A Novel prime-boost combinations of attenuated mycobacterium |
| 05/13/2009 | CN101432015A Functional antibodies |
| 05/13/2009 | CN101431999A Use of VX-702 for treating rheumatoid arthritis |
| 05/13/2009 | CN101429234A Vaccine based on simulating human blood vessel endothelial cell growth factor VEGF epitope and preparation method thereof |
| 05/13/2009 | CN101428145A Novel vaccine adjuvant |
| 05/13/2009 | CN101428144A Polysaccharide combined vaccine for epidemic encephalitis and preparation method thereof |
| 05/13/2009 | CN101428143A Attenuation bacteria carrier tuberculosis vaccine carrying tuberculosis, preparation method and application thereof |
| 05/13/2009 | CN101428006A Microparticle compositions and methods for the manufacture thereof |
| 05/13/2009 | CN100487119C Recombination newcastle disease LaSota weak virus vaccine for expressing poultry influenza virus H5 sub type HA protein |
| 05/13/2009 | CN100486996C Antibodies to human MCP-1 |
| 05/13/2009 | CN100486995C Compositions and methods for WT1 specific immunotherapy |
| 05/13/2009 | CN100486642C 疫苗 Vaccine |
| 05/13/2009 | CN100486444C Human colostrum-simulated biological milk powder |
| 05/12/2009 | US7531648 Gene therapy |
| 05/12/2009 | US7531643 Detection human integrin associated protein |
| 05/12/2009 | US7531636 A proinflammatory cytokine; monoclonal antibodies, or mixture of polyclonal antibodies; blocks signal transduction; hematopoietic cell proliferation |
| 05/12/2009 | US7531633 Immunotherapy against infection; harvesting antibodies directed against Staphylococcus from blood of immunized subject for use as immunotherapeutic agents |
| 05/12/2009 | US7531629 Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| 05/12/2009 | US7531507 Such as 3-tert-Butyl-D-alanyl-3-(6-trifluoromethylpyridin-3-yl)-L-alanyl-de(1-D-leucyl-2-L-leucyl)-lysobactin bistrifluoroacetate; cell wall biosynthesis inhibitors; treatment and/or prophylaxis of bacterial infectious diseases |
| 05/12/2009 | US7531504 Peptide antagonists of zonulin that bind to the zonula occludens receptor, yet do not physiologically modulate the opening of mammalian tight junctions; tablets, capsules |
| 05/12/2009 | US7531342 Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences |
| 05/12/2009 | US7531304 Method for screening FGFR-4 agonists |
| 05/12/2009 | US7531183 Biologically active hemagglutinin from type A Clostridium botulinum and methods of use |
| 05/12/2009 | US7531182 Vaccine against foot-and-mouth disease |
| 05/12/2009 | US7531181 Gp120 specific antigens and uses thereof |
| 05/12/2009 | US7531180 Chimeric alphavirus replicon particles |
| 05/12/2009 | US7531179 Bipolymer conjugate comprising botulin-a peptide for use in conferring tolerance to clostridial toxin |
| 05/12/2009 | US7531178 Immunoadhesin comprising a glycoprotein VI domain |
| 05/12/2009 | US7531177 Surface protein of leptospira |
| 05/12/2009 | US7531176 Brachyspira pilosicoli 72 kDa outer-membrane protein and diagnostic and therapeutic uses thereof |
| 05/12/2009 | US7531175 Methods for modulation of immune responses using humanized immunoglobulins reactive with B7-1 molecules |
| 05/12/2009 | US7531174 for in vitro diagnostics/antitumor agents; gene overexpression of cell surface proteins; genetic engineering; |
| 05/12/2009 | US7531171 Antibodies to non-functional P2X7 receptor |
| 05/12/2009 | US7531170 Administering an antibody that specifically binds to OX40 ligand (OX4L) sufficient to reduce or inhibit a recall immune response associated with or that causes asthma |
| 05/12/2009 | US7531169 or an antigen binding fragment comprising variable light chain region and heavy chain peptides, directed against isotypic determinants of immunoglobulin E (IgE), useful for diagnostics, prophylaxis and treatment of disease such as asthma, rhinitis, eczema, urticaria. dermatitis or food allergies |
| 05/12/2009 | US7531168 Method for downmodulating immune response in type I diabetes |
| 05/12/2009 | US7531166 IL-1β binding antibodies and fragments thereof |
| 05/12/2009 | CA2416869C Vaccines |
| 05/12/2009 | CA2415749C Method of producing infectious reovirus |
| 05/12/2009 | CA2412561C Highly efficient delivery of a large therapeutic mass aerosol |
| 05/12/2009 | CA2384301C Sustained-release drug formulations for implantation |
| 05/12/2009 | CA2284079C Immunotoxins and methods of inducing immune tolerance |
| 05/12/2009 | CA2272338C Immunization of infants |
| 05/12/2009 | CA2224709C Oral drugs and functional foods for treating and preventing rheumatoid arthritis |
| 05/12/2009 | CA2157864C Cloning and recombinant production of vespid venom enzymes, such as phospholipase and hyaluronidase, and immunological therapies based thereon |
| 05/12/2009 | CA2109977C Giardia vaccines |
| 05/11/2009 | CA2723226A1 Products and methods for stimulating an immune response |
| 05/07/2009 | WO2009059316A1 Fgf9-related methods for treating anxiety |
| 05/07/2009 | WO2009059281A1 Compositions and methods for using ca9 protein to stimulate an immune response |
| 05/07/2009 | WO2009059278A1 Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses |
| 05/07/2009 | WO2009059170A2 Ehrlichia canis diva (differentiate infection from vaccinated animals) |
| 05/07/2009 | WO2009059143A2 Use of toll-like receptor 4 antagonists for the treatment or prevention of osteoarthritic conditions |
| 05/07/2009 | WO2009059054A2 Bacteria strains an d bacteriocin produced therefrom |
| 05/07/2009 | WO2009058989A1 Antigen-antibody complexes as hiv-1 vaccines |
| 05/07/2009 | WO2009058957A2 Intranasal administration of active agents to the central nervous system |
| 05/07/2009 | WO2009058888A1 Combination therapy to treat persistent viral infections |
| 05/07/2009 | WO2009058870A1 Compositions and methods for modulating immune responses |
| 05/07/2009 | WO2009058835A1 Method of determining vaccine compliance |
| 05/07/2009 | WO2009058833A2 Mycoplasma bovis vaccine |
| 05/07/2009 | WO2009058734A1 Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
| 05/07/2009 | WO2009058662A2 Glucagon antagonists |
| 05/07/2009 | WO2009058492A2 Fc variants with altered binding to fcrn |
| 05/07/2009 | WO2009058383A2 Ligand |
| 05/07/2009 | WO2009058355A2 Chloroplast-derived human vaccine antigens against malaria |
| 05/07/2009 | WO2009057763A1 Novel adjuvant |
| 05/07/2009 | WO2009057664A1 Antibody and use thereof |
| 05/07/2009 | WO2009056965A2 A multicomponent or monocomponent vaccine to be used against chagas disease |
| 05/07/2009 | WO2009056671A1 Method for inhibiting angiogenesis or for treatment of cancer |
| 05/07/2009 | WO2009056651A1 Angiotensin-carrier formulation |
| 05/07/2009 | WO2009056631A2 Molecules and methods for modulating complement component |
| 05/07/2009 | WO2009056629A1 Fish vaccine |
| 05/07/2009 | WO2009056584A1 Anticomplement polypeptides of ixodes ricinus |
| 05/07/2009 | WO2009056541A1 Protection of an animal against pestivirus infection |
| 05/07/2009 | WO2009056535A2 Methods and kits for inducing a ctl response using a prime boost regimen |
| 05/07/2009 | WO2009056509A1 Improved nogo-a binding molecules and pharmaceutical use thereof |
| 05/07/2009 | WO2009056490A1 NEW ANTIBODIES SPECIFIC OF THE β-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS |
| 05/07/2009 | WO2009056342A1 Binding epitopes for g250 antibody |
| 05/07/2009 | WO2009056332A1 Use of modified cells for the treatment of multiple sclerosis |
| 05/07/2009 | WO2009056076A1 Engineered pertactin variants for vaccine use |
| 05/07/2009 | WO2009056075A1 Pharmaceutical composition containing protein nmb0873 |
| 05/07/2009 | WO2009055936A1 Humanized anti-venezuelan equine encephalitis virus recombinant antibodies |
| 05/07/2009 | WO2009055864A1 Methods and compositions for regulating airway tissue remodelling |
| 05/07/2009 | WO2009039388A3 Compositions and methods for detecting and treating ophthalmic disorders |
| 05/07/2009 | WO2009039175A3 Method for inhibiting bone resorption |
| 05/07/2009 | WO2009036407A3 Compositions and methods for regulating cellular protection |
| 05/07/2009 | WO2009036209A3 Homogeneous antibody populations |
| 05/07/2009 | WO2009035420A8 Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus h5-subtype or n1-subtype and uses thereof |
| 05/07/2009 | WO2009032256A3 Apc activators in combination with a cytokine-secreting cell and methods of use thereof |
| 05/07/2009 | WO2009032224A3 Compositions and methods for inhibiting squamous cell carcinoma |
| 05/07/2009 | WO2009023320A3 Modular linkers for conjugation of organic substances to substantially inorganic substances and methods of manufacture and use thereof |
| 05/07/2009 | WO2009020645A3 Matriptase protein and uses thereof |
| 05/07/2009 | WO2009007298A3 Allergens from aspergillus versicolor, and method of detecting a mold allergy caused by interior rooms |
| 05/07/2009 | WO2009007244A3 Replication deficient influenza virus for the expression of heterologous sequences |